ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director directly owned 38,878 shares of the company’s stock, valued at $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Stock Up 0.0%
NASDAQ ANIP opened at $81.68 on Friday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a fifty day moving average of $79.72 and a two-hundred day moving average of $79.42. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of 20.68 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 52 week low of $61.17 and a 52 week high of $99.50.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Analysis on ANIP
Institutional Trading of ANI Pharmaceuticals
A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the period. State Street Corp boosted its stake in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after purchasing an additional 15,496 shares during the period. UBS Group AG boosted its stake in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after purchasing an additional 91,153 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 8.9% during the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after purchasing an additional 43,523 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
- Five stocks we like better than ANI Pharmaceuticals
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
